Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV. Pour L, et al. Among authors: bakker na. Haematologica. 2024 Mar 1;109(3):895-905. doi: 10.3324/haematol.2023.283509. Haematologica. 2024. PMID: 37646660 Free PMC article. Clinical Trial.
Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies.
Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV. Sonneveld P, et al. Among authors: bakker na. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):687-696. doi: 10.1016/j.clml.2023.05.004. Epub 2023 May 6. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37355418 Free article.
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study.
Ocio EM, Efebera YA, Hájek R, Straub J, Maisnar V, Eveillard JR, Karlin L, Mateos MV, Oriol A, Ribrag V, Richardson PG, Norin S, Obermüller J, Bakker NA, Pour L. Ocio EM, et al. Among authors: bakker na. Haematologica. 2024 Mar 1;109(3):867-876. doi: 10.3324/haematol.2023.283490. Haematologica. 2024. PMID: 37646657 Free PMC article. Clinical Trial.
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study.
Schjesvold FH, Ludwig H, Delimpasi S, Robak P, Coriu D, Tomczak W, Pour L, Spicka I, Dimopoulos MA, Masszi T, Chernova NG, Sandberg A, Thuresson M, Norin S, Bakker NA, Mateos MV, Richardson PG, Sonneveld P. Schjesvold FH, et al. Among authors: bakker na. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.284635. Online ahead of print. Haematologica. 2024. PMID: 38426292 Free article.
PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma.
Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, Thuresson M, Huledal G, Norin S, Bakker NA, Minarik J. Pour L, et al. Among authors: bakker na. Clin Lymphoma Myeloma Leuk. 2024 Feb 23:S2152-2650(24)00091-0. doi: 10.1016/j.clml.2024.02.012. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38490927 Free article.
Grambank reveals the importance of genealogical constraints on linguistic diversity and highlights the impact of language loss.
Skirgård H, Haynie HJ, Blasi DE, Hammarström H, Collins J, Latarche JJ, Lesage J, Weber T, Witzlack-Makarevich A, Passmore S, Chira A, Maurits L, Dinnage R, Dunn M, Reesink G, Singer R, Bowern C, Epps P, Hill J, Vesakoski O, Robbeets M, Abbas NK, Auer D, Bakker NA, Barbos G, Borges RD, Danielsen S, Dorenbusch L, Dorn E, Elliott J, Falcone G, Fischer J, Ghanggo Ate Y, Gibson H, Göbel HP, Goodall JA, Gruner V, Harvey A, Hayes R, Heer L, Herrera Miranda RE, Hübler N, Huntington-Rainey B, Ivani JK, Johns M, Just E, Kashima E, Kipf C, Klingenberg JV, König N, Koti A, Kowalik RGA, Krasnoukhova O, Lindvall NLM, Lorenzen M, Lutzenberger H, Martins TRA, Mata German C, van der Meer S, Montoya Samamé J, Müller M, Muradoglu S, Neely K, Nickel J, Norvik M, Oluoch CA, Peacock J, Pearey IOC, Peck N, Petit S, Pieper S, Poblete M, Prestipino D, Raabe L, Raja A, Reimringer J, Rey SC, Rizaew J, Ruppert E, Salmon KK, Sammet J, Schembri R, Schlabbach L, Schmidt FWP, Skilton A, Smith WD, de Sousa H, Sverredal K, Valle D, Vera J, Voß J, Witte T, Wu H, Yam S, Ye J, Yong M, Yuditha T, Zariquiey R, Forkel R, Evans N, Levinson SC, Haspelmath M, Greenhill SJ, Atkinson QD, Gray RD. Skirgård H, et al. Among authors: bakker na. Sci Adv. 2023 Apr 21;9(16):eadg6175. doi: 10.1126/sciadv.adg6175. Epub 2023 Apr 19. Sci Adv. 2023. PMID: 37075104 Free PMC article.
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, Champanhet E, Garner H, Sikorska K, Loo CE, Kemper I, Mandjes IAM, de Maaker M, van Geel JJL, Boers J, de Boer M, Salgado R, van Dongen MGJ, Sonke GS, de Visser KE, Schumacher TN, Blank CU, Wessels LFA, Jager A, Tjan-Heijnen VCG, Schröder CP, Linn SC, Kok M. Voorwerk L, et al. Among authors: bakker nam. Nat Cancer. 2023 Apr;4(4):535-549. doi: 10.1038/s43018-023-00542-x. Epub 2023 Apr 10. Nat Cancer. 2023. PMID: 37038006 Free PMC article. Clinical Trial.
MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial.
Rohaan MW, Gomez-Eerland R, van den Berg JH, Geukes Foppen MH, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker NAM, van den Broek D, Pronk LM, Grijpink-Ongering LG, Sari A, Kessels R, van den Haak M, Mallo HA, Karger M, van de Wiel BA, Zuur CL, Duinkerken CW, Lalezari F, van Thienen JV, Wilgenhof S, Blank CU, Beijnen JH, Nuijen B, Schumacher TN, Haanen JBAG. Rohaan MW, et al. Among authors: bakker nam. Immunooncol Technol. 2022 Jun 18;15:100089. doi: 10.1016/j.iotech.2022.100089. eCollection 2022 Sep. Immunooncol Technol. 2022. PMID: 35865122 Free PMC article.
65 results